[{"orgOrder":0,"company":"North Florida Foundation for Research and Education","sponsor":"North Florida\/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"||Androgen Receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"North Florida Foundation for Research and Education","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"North Florida Foundation for Research and Education \/ North Florida\/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"North Florida Foundation for Research and Education \/ North Florida\/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Tulane University","sponsor":"LSU Health Sciences Center New Orleans | Antares Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"||Androgen Receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Tulane University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tulane University \/ LSU Health Sciences Center New Orleans | Antares Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Tulane University \/ LSU Health Sciences Center New Orleans | Antares Pharma"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"||Androgen Receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Halozyme Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","sponsor":"Bayer AG | The George Institute | HMRI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Enanthate","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group \/ Bayer AG | The George Institute | HMRI","highestDevelopmentStatusID":"8","companyTruncated":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group \/ Bayer AG | The George Institute | HMRI"}]

Find Clinical Drug Pipeline Developments & Deals for Rotexmedica brand of testosterone enanthate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Endocrinology

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Testosterone enantate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone.

                          Product Name : Testosterone Enantate Ever Pharma

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 19, 2024

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Ever Pharma CB

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 14, 2024

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Australian and New Zealand Urogenital and Prostate Cancer Trials Group

                          Country arrow
                          EPSC
                          Not Confirmed

                          Australian and New Zealand Urogenital and Prostate Cancer Trials Group

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Bayer AG | The George Institute | HMRI

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Tulane University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Tulane University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Xyosted

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 23, 2020

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : LSU Health Sciences Center New Orleans | Antares Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          North Florida Foundation for Research and Education

                          Country arrow
                          EPSC
                          Not Confirmed

                          North Florida Foundation for Research and Education

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Study Phase : Phase II

                          Sponsor : North Florida/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 08, 2020

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : North Florida/South Georgia Veterans Health System | Brooks Rehabilitation | University of Florida | VA Eastern Colorado Health Care System

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          University of Washington

                          Country arrow
                          EPSC
                          Not Confirmed

                          University of Washington

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 04, 2018

                          Lead Product(s) : Olaparib,Testosterone Enanthate,Testosterone Cypionate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : National Cancer Institute | AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 19, 2016

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pennington Biomedical Research Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Pennington Biomedical Research Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase IV

                          Sponsor : United States Army Research Institute of Environmental Medicine | MyoSyntax | Defence Research and Development Canada | US Department of Defense

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 12, 2016

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : United States Army Research Institute of Environmental Medicine | MyoSyntax | Defence Research and Development Canada | US Department of Defense

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 22, 2015

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 08, 2014

                          Lead Product(s) : Testosterone Enanthate,Inapplicable

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank